Table 2.

Different variables related to the biological therapy (naïve for biologics, multifailure for biologic drug, treatment interruption, type of interleukin inhibitors, drug distribution) are plotted in relation to different age groups. In bold significant value (p < 0.05).

Naive for Biologic				Multifailure for Biologic Drug
Age Group	No	Yes	p	Age Group	No	Yes	p
>65	41.37%	58.63%	0.008	>65	97.84%	2.16%	0.044
65–41	38.02%	61.98%		65–41	99.48%	0.52%
40–26	27.95%	72.05%		40–26	100%	0%
<26	22.5%	77.5%		<26	100%	0%
Treatment interruption				Type of interleukin inhibitors
Age group	No	Yes	p	Age group	IL-17	IL-23	p
>65	77.34%	22.66%	0.259	>65	62.95%	37.05%	0.005
65–41	81.08%	18.92%		65–41	63.54%	36.46%
40–26	84.47%	15.53%		40–26	55.9%	44.1%
<26	85%	15%		<26	37.5%	62.5%
Drug distribution
Age group	Risankizumab	Guselkumab	Secukinumab	Brodalumab	Tildrakizumab	Ixekizumab	p
>65	17.63%	2.88%	25.9%	19.42%	16.55%	17.63%	<0.001
65–41	22.92%	6.6%	26.56%	17.19%	6.94%	19.79%
40–26	27.33%	11.8%	16.77%	24.22%	4.97%	14.91%
<26	27.5%	22.5%	7.5%	25%	12.5%	5%